Clinical importance of biocompatibility and its effect on haemodialysis treatment.
Opatrný
Karel
K
Department of Medicine I, Charles University Medical School, Pilsen, Czech Republic. apatrny@fnplzen.cz
D001672:Biocompatible Materials; D001920:Bradykinin / Q000009:adverse effects; D003167:Complement Activation; D005027:Ethylene Oxide / Q000009:adverse effects; D005260:Female; D005466:Fluorocarbons / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000401:mortality*; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008567:Membranes, Artificial; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods; D018570:Risk Assessment; D016019:Survival Analysis
D001672:Biocompatible Materials; D005466:Fluorocarbons; D008567:Membranes, Artificial; D005027:Ethylene Oxide; D001920:Bradykinin